NDLI: Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

Content Provider	Springer Nature : BioMed Central
Author	van Marcke, C. Honoré, N. van der Elst, A. Beyaert, S. Derouane, F. Dumont, C. Aboubakar Nana, F. Baurain, J. F. Borbath, I. Collard, P. Cornélis, F. De Cuyper, A. Duhoux, F. P. Filleul, B. Galot, R. Gizzi, M. Mazzeo, F. Pieters, T. Seront, E. Sinapi, I. Van den Eynde, M. Whenham, N. Yombi, J. C. Scohy, A. van Maanen, A. Machiels, J. P.
Abstract	Background The viral pandemic coronavirus disease 2019 (COVID-19) has disrupted cancer patient management around the world. Most reported data relate to incidence, risk factors, and outcome of severe COVID-19. The safety of systemic anti-cancer therapy in oncology patients with non-severe COVID-19 is an important matter in daily practice. Methods ONCOSARS-1 was a single-center, academic observational study. Adult patients with solid tumors treated in the oncology day unit with systemic anti-cancer therapy during the initial phase of the COVID-19 pandemic in Belgium were prospectively included. All patients (n = 363) underwent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) serological testing after the first peak of the pandemic in Belgium. Additionally, 141 of these patients also had a SARS-CoV-2 RT-PCR test during the pandemic. The main objective was to retrospectively determine the safety of systemic cancer treatment, measured by the rate of adverse events according to the Common Terminology Criteria for Adverse Events, in SARS-CoV-2-positive patients compared with SARS-CoV-2-negative patients. Results Twenty-two (6%) of the 363 eligible patients were positive for SARS-CoV-2 by RT-PCR and/or serology. Of these, three required transient oxygen supplementation, but none required admission to the intensive care unit. Hematotoxicity was the only adverse event more frequently observed in SARS-CoV-2 -positive patients than in SARS-CoV-2-negative patients: 73% vs 35% (P < 0.001). This association remained significant (odds ratio (OR) 4.1, P = 0.009) even after adjusting for performance status and type of systemic treatment. Hematological adverse events led to more treatment delays for the SARS-CoV-2-positive group: 55% vs 20% (P < 0.001). Median duration of treatment interruption was similar between the two groups: 14 and 11 days, respectively. Febrile neutropenia, infections unrelated to COVID-19, and bleeding events occurred at a low rate in the SARS-CoV-2-positive patients. Conclusion Systemic anti-cancer therapy appeared safe in ambulatory oncology patients treated during the COVID-19 pandemic. There were, however, more treatment delays in the SARS-CoV-2-positive population, mainly due to a higher rate of hematological adverse events.
Related Links	https://bmccancer.biomedcentral.com/counter/pdf/10.1186/s12885-021-08349-8.pdf
Ending Page	12
Page Count	12
Starting Page	1
File Format	HTM / HTML
ISSN	14712407
DOI	10.1186/s12885-021-08349-8
Journal	BMC Cancer
Issue Number	1
Volume Number	21
Language	English
Publisher	BioMed Central
Publisher Date	2021-05-20
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Surgical Oncology Health Promotion and Disease Prevention Biomedicine Medicine Public Health Systemic anti-cancer treatment Non-severe COVID-19 Ambulatory Safety Medicine/Public Health
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology Genetics
Journal Impact Factor	3.4/2023
5-Year Journal Impact Factor	3.8/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants

Primary care utilization for patients with newly diagnosed cancer during the COVID-19 pandemic: a population-based study

The effects of the COVID-19 pandemic on psychological stress in breast cancer patients

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran

Subsequent thyroid disorders associated with treatment strategy in head and neck cancer patients: a nationwide cohort study

Short-term and long-term outcomes of patients with gastric cancer during versus before the COVID-19 pandemic: cohort study using propensity score matching method

Systemic treatment in patients with malignant pleural mesothelioma – real life experience

Risk of cardiovascular diseases in cancer patients: A nationwide representative cohort study in Taiwan

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

Similar Documents

The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants

Primary care utilization for patients with newly diagnosed cancer during the COVID-19 pandemic: a population-based study

The effects of the COVID-19 pandemic on psychological stress in breast cancer patients

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study

Hospital and post-discharge mortality in COVID-19 patients with a preexisting cancer diagnosis in Iran

Subsequent thyroid disorders associated with treatment strategy in head and neck cancer patients: a nationwide cohort study

Short-term and long-term outcomes of patients with gastric cancer during versus before the COVID-19 pandemic: cohort study using propensity score matching method

Systemic treatment in patients with malignant pleural mesothelioma – real life experience

Risk of cardiovascular diseases in cancer patients: A nationwide representative cohort study in Taiwan

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study